Acta Scientific Pharmaceutical Sciences

OpinionVolume 1 Issue 6

Drugs Acting on Imidazoline Receptor are Still in Infancy for Treating the Diabetes Mellitus

Marwan S Al-Nimer1,2,3*

1Visitor Professor of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq
2Visitor Professor of Pharmacology, College of Medicine, Sulaimani University, Sulaimani, Iraq
3Professor of Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq

*Corresponding Author: Marwan S Al-Nimer, Visitor Professor of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil and Visitor Professor of Pharmacology, College of Medicine, Sulaimani University, Sulaimani, and Professor of Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.

Received: September 19, 2017; Published: December 12, 2017

Citation: Marwan S Al-Nimer. “Drugs Acting on Imidazoline Receptor are Still in Infancy for Treating the Diabetes Mellitus”. Acta Scientific Pharmaceutical Sciences 1.6 (2018).

  Imidazoline receptors (I) are distributed in the central nervous system and in peripheral tissue. They involved in the regulation of the blood pressure and secretion of hormones, including adrenocorticotrophic hormone and insulin. Drugs that are selectively act on I-receptor showed pleotropic effects, including anti- inflammatory; protection of central nervous system against stress, pain, convulsion and depression; regulation of body fat; and cell protection against apoptosis and adhesion. Several studies found that there is a heterogenous group of substances that served as a ligand for imidazoline receptors. Canavanine activates the I-2 and thereby reduced the hyperglycemia that induced by streptozocin in animal [1]. Allantoin, a byproduct of uric acid and is the primary active substance of the Yam (Dioscorea spp.) activates the I-3 re-ceptors and it ameliorates the apoptotic changes in the pancreatic beta-cell that induced by streptozocin and thereby attenuates the hyperglycemia [2].

Copyright: © 2018 Marwan S Al-Nimer. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Member In



News and Events


  • Submission Timeline for Regular Issue
    Last date for submission of articles for regular Issues is October 30, 2019.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US